• Je něco špatně v tomto záznamu ?

Flavonolignans from silymarin modulate antibiotic resistance and virulence in Staphylococcus aureus

K. Holasová, B. Křížkovská, L. Hoang, S. Dobiasová, J. Lipov, T. Macek, V. Křen, K. Valentová, T. Ruml, J. Viktorová

. 2022 ; 149 (-) : 112806. [pub] 20220315

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018520

Antibiotic resistance is currently a serious health problem. Since the discovery of new antibiotics no longer seems to be a sufficient tool in the fight against multidrug-resistant infections, adjuvant (combination) therapy is gaining in importance as well as reducing bacterial virulence. Silymarin is a complex of flavonoids and flavonolignans known for its broad spectrum of biological activities, including its ability to modulate drug resistance in cancer. This work aimed to test eleven, optically pure silymarin flavonolignans for their ability to reverse the multidrug resistance phenotype of Staphylococcus aureus and reduce its virulence. Silybin A, 2,3-dehydrosilybin B, and 2,3-dehydrosilybin AB completely reversed antibiotic resistance at concentrations of 20 μM or less. Both 2,3-dehydrosilybin B and AB decreased the antibiotic-induced gene expression of representative efflux pumps belonging to the major facilitator (MFS), multidrug and toxic compound extrusion (MATE), and ATP-binding cassette (ABC) families. 2,3-Dehydrosilybin B also inhibited ethidium bromide accumulation and efflux in a clinical isolate whose NorA and MdeA overproduction was induced by antibiotics. Most of the tested flavonolignans reduced cell-to-cell communication on a tetrahydrofuran-borate (autoinducer-2) basis, with isosilychristin leading the way followed by 2,3-dehydrosilybin A and AB, which halved communication at 10 μM. Anhydrosilychristin was the only compound that reduced communication based on acyl-homoserine lactone (autoinducer 1), with an IC50 of 4.8 μM. Except for isosilychristin and anhydrosilychristin, all of the flavonolignans inhibited S. aureus surface colonization, with 2,3-dehydrosilybin A being the most active (IC50 10.6 μM). In conclusion, the selected flavonolignans, particularly derivatives of 2,3-dehydrosilybin B, 2,3-dehydrosilybin AB, and silybin A are non-toxic modulators of S. aureus multidrug resistance and can decrease the virulence of the bacterium, which deserves further detailed research.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018520
003      
CZ-PrNML
005      
20220804134828.0
007      
ta
008      
220720s2022 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.biopha.2022.112806 $2 doi
035    __
$a (PubMed)35303568
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Holasová, Kateřina $u Department of Biochemistry and Microbiology, Faculty of Food and Biochemical Technology, University of Chemistry and Technology, Prague, Technická 3, Prague 166 28, Czech Republic. Electronic address: rehorova@vscht.cz
245    10
$a Flavonolignans from silymarin modulate antibiotic resistance and virulence in Staphylococcus aureus / $c K. Holasová, B. Křížkovská, L. Hoang, S. Dobiasová, J. Lipov, T. Macek, V. Křen, K. Valentová, T. Ruml, J. Viktorová
520    9_
$a Antibiotic resistance is currently a serious health problem. Since the discovery of new antibiotics no longer seems to be a sufficient tool in the fight against multidrug-resistant infections, adjuvant (combination) therapy is gaining in importance as well as reducing bacterial virulence. Silymarin is a complex of flavonoids and flavonolignans known for its broad spectrum of biological activities, including its ability to modulate drug resistance in cancer. This work aimed to test eleven, optically pure silymarin flavonolignans for their ability to reverse the multidrug resistance phenotype of Staphylococcus aureus and reduce its virulence. Silybin A, 2,3-dehydrosilybin B, and 2,3-dehydrosilybin AB completely reversed antibiotic resistance at concentrations of 20 μM or less. Both 2,3-dehydrosilybin B and AB decreased the antibiotic-induced gene expression of representative efflux pumps belonging to the major facilitator (MFS), multidrug and toxic compound extrusion (MATE), and ATP-binding cassette (ABC) families. 2,3-Dehydrosilybin B also inhibited ethidium bromide accumulation and efflux in a clinical isolate whose NorA and MdeA overproduction was induced by antibiotics. Most of the tested flavonolignans reduced cell-to-cell communication on a tetrahydrofuran-borate (autoinducer-2) basis, with isosilychristin leading the way followed by 2,3-dehydrosilybin A and AB, which halved communication at 10 μM. Anhydrosilychristin was the only compound that reduced communication based on acyl-homoserine lactone (autoinducer 1), with an IC50 of 4.8 μM. Except for isosilychristin and anhydrosilychristin, all of the flavonolignans inhibited S. aureus surface colonization, with 2,3-dehydrosilybin A being the most active (IC50 10.6 μM). In conclusion, the selected flavonolignans, particularly derivatives of 2,3-dehydrosilybin B, 2,3-dehydrosilybin AB, and silybin A are non-toxic modulators of S. aureus multidrug resistance and can decrease the virulence of the bacterium, which deserves further detailed research.
650    _2
$a antibakteriální látky $x farmakologie $7 D000900
650    _2
$a antibiotická rezistence $7 D004352
650    _2
$a lidé $7 D006801
650    _2
$a silibinin $x farmakologie $7 D000077385
650    12
$a silymarin $x chemie $x farmakologie $7 D012838
650    12
$a stafylokokové infekce $7 D013203
650    _2
$a Staphylococcus aureus $7 D013211
650    _2
$a virulence $7 D014774
655    _2
$a časopisecké články $7 D016428
700    1_
$a Křížkovská, Bára $u Department of Biochemistry and Microbiology, Faculty of Food and Biochemical Technology, University of Chemistry and Technology, Prague, Technická 3, Prague 166 28, Czech Republic. Electronic address: krizkova@vscht.cz
700    1_
$a Hoang, Lan $u Department of Biochemistry and Microbiology, Faculty of Food and Biochemical Technology, University of Chemistry and Technology, Prague, Technická 3, Prague 166 28, Czech Republic. Electronic address: hoangl@vscht.cz
700    1_
$a Dobiasová, Simona $u Department of Biochemistry and Microbiology, Faculty of Food and Biochemical Technology, University of Chemistry and Technology, Prague, Technická 3, Prague 166 28, Czech Republic. Electronic address: dobiasos@vscht.cz
700    1_
$a Lipov, Jan $u Department of Biochemistry and Microbiology, Faculty of Food and Biochemical Technology, University of Chemistry and Technology, Prague, Technická 3, Prague 166 28, Czech Republic. Electronic address: lipovj@vscht.cz
700    1_
$a Macek, Tomáš $u Department of Biochemistry and Microbiology, Faculty of Food and Biochemical Technology, University of Chemistry and Technology, Prague, Technická 3, Prague 166 28, Czech Republic. Electronic address: tomas.macek@vscht.cz
700    1_
$a Křen, Vladimír $u Laboratory of Biotransformation, Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ 142 20 Prague, Czech Republic. Electronic address: kren@biomed.cas.cz
700    1_
$a Valentová, Kateřina $u Laboratory of Biotransformation, Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ 142 20 Prague, Czech Republic. Electronic address: kata.valentova@email.cz
700    1_
$a Ruml, Tomáš $u Department of Biochemistry and Microbiology, Faculty of Food and Biochemical Technology, University of Chemistry and Technology, Prague, Technická 3, Prague 166 28, Czech Republic. Electronic address: rumlt@vscht.cz
700    1_
$a Viktorová, Jitka $u Department of Biochemistry and Microbiology, Faculty of Food and Biochemical Technology, University of Chemistry and Technology, Prague, Technická 3, Prague 166 28, Czech Republic. Electronic address: prokesoj@vscht.cz
773    0_
$w MED00005486 $t Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie $x 1950-6007 $g Roč. 149, č. - (2022), s. 112806
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35303568 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134822 $b ABA008
999    __
$a ok $b bmc $g 1822217 $s 1169763
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 149 $c - $d 112806 $e 20220315 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...